Loading market dashboard
Abbott Laboratories
ABTHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis PR Newswire A
Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in intervention Nearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1 ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes.
Abbott Laboratories must defend against a proposed class-action lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinically proven" to help children grow taller, a federal judge ruled on Thursday.
ABT wins the CE Mark for Libre Duo sensors that track glucose and ketones every minute, aiming to spot DKA risks earlier and reduce routine testing.
On June 02, 2026, we take a closer look at the DCF analysis for Abbott Laboratories (ABT). The stock has experienced notable price performance, with a year-to-d
Don't wait too long to buy the dip on these stocks.
ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.
ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.
First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providers Designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes.
Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based options Recent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payers ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC.
Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show low anxiety and minimal psychological burden in real-world use ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago.
When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.
They have increased their payouts for a combined 171 years straight.
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Build-A-Bear Workshop and Abbott Laboratories are compelling dividend stocks, each trading near lows with yields close to 3%. BBW offers a debt-free balance sheet, aggressive share repurchases, and international expansion, positioning for 9.3% earnings CAGR and over 70% upside to its $62 target. ABT, trading at a forward P/E of 15.31x, is undervalued with robust liquidity, ongoing buybacks, and insider buying, despite segment weakness and lowered guidance.
BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Abbott Laboratories trades at a decade low of 17.7x forward earnings despite 13.2% Q1 2026 Medical Devices growth and a 54-year dividend streak. Three underappreciated catalysts—Exact Sciences synergy, CMS CGM expansion, and Nutrition margin recovery—could drive $1.27–$1.73 incremental EPS by 2028–2029. Consensus underestimates ABT's commercial leverage, with distribution synergies and CMS reimbursement expansion offering asymmetric upside not priced into current models.
Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak.
ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.
These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Q1 2026, Polen Focus Growth Portfolio returned -17.27% (net of fees) compared to -9.78% for the Index. Starbucks was the top performing absolute and relative contributor in Q1 amid positive signs that CEO Brian Nicol's multi-year turnaround strategy is beginning to bear fruit. In Q1 2026, we initiated new positions in Lam Research, Meta and Rollins, while we sold our holdings in Abbott Laboratories, Adobe, and Boston Scientific, Paycom and Intuit.
Abbott Laboratories (ABT 1.47%) is offering income investors a rare setup: a yield is approaching 3% while the business continues to grow. The stock isn't a screaming bargain, and rising costs matter, but its record as a Dividend King (increasing its dividends for 50+ consecutive years) makes this healthcare giant worth a closer look.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
This company, which has raised its dividend for 54 consecutive years, is on sale.
Abbott Laboratories is a very diversified company, which can reduce some risks. The medical products maker is a committed dividend payer, too, with a solid yield.
Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery The integrated imaging platform is designed to enable fast, intuitive decision making for physicians while treating complex coronary disease to open clogged arteries The AI enabled software helps physicians size and position the stent more accurately, which can lead to better results for patients ABBOTT PARK, Ill., April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software.
Comerica Bank trimmed its stake in shares of Abbott Laboratories (NYSE: ABT) by 3.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 735,393 shares of the healthcare product maker's stock after selling 29,650 shares during the period. Comerica Bank's
Aprio Wealth Management LLC boosted its holdings in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 14,700 shares of the healthcare product maker's stock after purchasing an additional 7,861 shares during the period. Aprio Wealth Management
Advisors Capital Management LLC increased its holdings in shares of Abbott Laboratories (NYSE: ABT) by 3.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 209,652 shares of the healthcare product maker's stock after purchasing an additional 6,743 shares during the quarter.
Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cases New data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablation Two new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system ABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.
Dividend Kings are outperforming SPY year-to-date, with 36 of 58 beating the index with an average gain of 7.03% versus SPY's 4.18%. Twenty-seven Dividend Kings are both potentially undervalued and offer a long-term annualized expected return of at least 10%. Recent dividend increases among Kings have been modest, with the average 2026 dividend growth rate rising to 3.11%.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
After reaching a cycle high of $141.23 per share in early March 2025, Abbott Laboratories closed at $92.48 as of April 23rd, the equivalent of a ~35% decline in just over a year. This is now one of the most severe drawdowns in the company's history, even exceeding in severity the price declines experienced during the 2008-09 global financial crisis. Along with the release of the Q1-26 earnings last week, management has guided for adjusted diluted EPS between $5.38 and $5.58 per share in fiscal 2026.
Arizona State Retirement System lowered its stake in Abbott Laboratories (NYSE: ABT) by 2.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 494,902 shares of the healthcare product maker's stock after selling 13,152 shares during the quarter. Arizona State Retirement System's holdings
Eagleford Energy (OTCMKTS:GRUSF - Get Free Report) and Abbott Laboratories (NYSE: ABT - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability. Insider and Institutional Ownership 9.3% of Eagleford Energy
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott Laboratories (ABT) offers a 2.5% dividend yield, over 50 years of increases, and trades at a forward P/E below its 5-year average. Recent post-earnings sell-off, driven by lowered EPS guidance and Nutrition segment weakness, presents a compelling long-term buying opportunity. ABT's balance sheet remains robust with $8.5B in cash, manageable debt, and projected 40.5% free cash flow growth by 2028.
Boston Scientific (NYSE: BSX) trades around $61, with analyst price targets ranging from $69 (conservative) to $124 (optimistic), implying substantial upside.
Investors need to pay close attention to ABT stock based on the movements in the options market lately.
Abbott Laboratories presents a compelling buy-the-dip opportunity, as short-term headwinds and conservative guidance overshadow its durable, diversified growth platform. ABT's diversified healthcare platform is reshaping toward higher-growth areas, highlighted by the Exact Sciences acquisition, expected to add $3B in sales this year. Medical devices and pharmaceuticals segments continue to deliver above-market growth, while the dividend remains well-covered, with a 2.6% yield and 8.5% 5-year CAGR.
Finivi Inc. decreased its position in Abbott Laboratories (NYSE: ABT) by 71.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,175 shares of the healthcare product maker's stock after selling 5,434 shares during the period. Finivi Inc.'s
Abbott Laboratories and Dexcom are the biggest players in the market for continuous glucose monitoring devices. Abbott has a vast lineup of products beyond that and an overall diversified healthcare business.
On April 20, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has faced significant price performance challenges recently, wit
Whether Abbott Laboratories (NYSE: ABT | ABT Price Prediction) stock is at a good entry point depends on your investment horizon and tolerance for near-term uncertainty.
These healthcare stocks offer long track records of solid performance. They declined with the general market in recent times, offering savvy long-term investors a fresh buying opportunity.
Lbp Am Sa decreased its position in Abbott Laboratories (NYSE: ABT) by 67.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,220 shares of the healthcare product maker's stock after selling 30,962 shares during the period. Lbp Am
Abbott Laboratories (NYSE: ABT) reported first-quarter 2026 results that management said were "aligned with our expectations for the start of the year," as the company absorbed weaker respiratory testing demand and earlier-than-planned financing costs tied to its newly closed acquisition of Exact Sciences. Chairman and CEO Robert Ford said Abbott delivered adjusted earnings per share of
Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCED ABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard® test.
Abbott Laboratories TodayABTAbbott Laboratories$96.42 +0.95 (+1.00%) As of 10:45 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$93.92▼$139.06Dividend Yield2.61%P/E Ratio25.86Price Target$121.00Add to Watchlist
Abbott Laboratories (NYSE: ABT) on Thursday posted upbeat first-quarter earnings but revised its 2026 earnings outlook below expectations.
